Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China flag China · Delayed Price · Currency is CNY
54.97
+0.79 (1.46%)
Aug 11, 2026, 3:00 PM CST

SHA:600276 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
8,1197,7116,3374,3023,9064,530
Depreciation & Amortization
843.38843.38776.03704.64577.89520.41
Other Amortization
99.0999.0994.7989.366.2620.33
Loss (Gain) From Sale of Assets
-4.05-4.05-5.4-3.16-5.47-3.37
Asset Writedown & Restructuring Costs
72.2672.264.9476.21131.24-117.52
Loss (Gain) From Sale of Investments
-116.09-116.09-132.535.62-533.84-169.57
Provision & Write-off of Bad Debts
19.0219.02-28.67-15.7726.02-3.87
Other Operating Activities
226.29403.2330.8317.02-67.79-27.8
Change in Accounts Receivable
-1,097-1,097-375.72,036-2,285-868.27
Change in Inventory
-479.24-479.24-135.63129.11-52.68-631.22
Change in Accounts Payable
4,1354,135671.41315.32-511.05809.7
Change in Other Net Operating Assets
53.0253.02209.2655.4734.98253.16
Operating Cash Flow
11,46711,2357,4237,6441,2654,219
Operating Cash Flow Growth
70.55%51.36%-2.89%504.12%-70.01%22.93%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2,965-2,962-1,969-1,484-1,992-1,665
Sale of Property, Plant & Equipment
28.218.9121.920.1820.2116.11
Divestitures
----36.05-
Investment in Securities
-29.3151-17.22,5902,160842.49
Other Investing Activities
33.2251.4952.5195.51166.49259.77
Investing Cash Flow
-2,933-2,741-1,9121,222390.29-546.26

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----1,260-
Long-Term Debt Issued
-1,496799.9121.1--
Total Debt Issued
1,7951,496799.9121.11,260-
Long-Term Debt Repaid
--1,544-847.28-1,315-36.28-31.05
Net Debt Issued (Repaid)
-48.69-48.23-47.38-1,2941,224-31.05
Issuance of Common Stock
10,77010,770----
Repurchase of Common Stock
-978.15-978.15-228.43-827.26-1,066-235.16
Common Dividends Paid
-1,284-1,284-1,275-1,023-1,016-1,066
Other Financing Activities
-201.95-677.76--538.86334.14
Financing Cash Flow
8,2577,782-1,551-3,144-318.77-998.32

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-739.46-360.137.412.5380.5-16.87
Net Cash Flow
16,05215,9163,9685,7341,4172,657

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
8,5028,2735,4546,160-726.912,554
Free Cash Flow Growth
84.30%51.71%-11.47%---11.24%
Free Cash Flow Margin
26.11%26.16%19.49%26.99%-3.42%9.86%
Free Cash Flow Per Share
1.281.270.860.97-0.110.40
Levered Free Cash Flow
6,3085,8594,3914,866-2,0301,151
Unlevered Free Cash Flow
6,3105,8684,3944,869-2,0261,154

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
2,8332,7872,2901,5681,6311,607
Change in Working Capital
2,2072,207346.192,437-2,835-530.01